Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma
Sponsor: sigma-tau i.f.r. S.p.A.
A PHASE2 clinical study on Malignant Melanoma, this trial is completed. The trial is conducted by sigma-tau i.f.r. S.p.A. and has accumulated 7 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- sigma-tau i.f.r. S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aarau, Switzerland , Agrigento, Italy , Albano Laziale, Italy , Barcelona, Spain , Berlin, Germany , Budapest, Hungary , Buxtehude, Germany , Caltanissetta, Italy , Catania, Italy and 46 more locations